Shilpa Medicare Limited — Important, 03-04-2025: General Updates

Shilpa Medicare has announced a board meeting regarding the launch of BORUZU™, a new 3.5mg/1.4ml injection formulation of bortezomib for subcutaneous or intravenous use, in partnership with Amneal Pharmaceuticals. This ready-to-use oncology product aims to streamline administration by reducing preparation steps and has received a permanent J-code from the U.S. Centers for Medicare & Medicaid Services. The launch reinforces Shilpa's commitment to innovate in oncology treatments and could positively impact operational efficiencies and patient compliance. Investors may view this development as a strategic opportunity to strengthen market presence in the oncology sector.